Glycopyrrolate/rivastigmine

Drug Profile

Glycopyrrolate/rivastigmine

Alternative Names: RVT 104

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Axovant Sciences
  • Class Antidementias; Phenylcarbamates; Pyrrolidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease; Lewy body disease

Most Recent Events

  • 15 Aug 2016 Early research in Alzheimer's disease in Bermuda (unspecified route) after August 2016
  • 15 Aug 2016 Early research in Lewy body disease in Bermuda (unspecified route) after August 2016
  • 01 Aug 2016 Axovant and Qaam Pharmaceuticals enters into an exclusive license agreement to develop and commercialise products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top